NEW YORK – Interim results from an ongoing Phase II basket trial have demonstrated that the combination of dabrafenib and trametinib (Novartis' Tafinlar and Mekinist) may benefit patients with BRAF V600E mutated cholangiocarcinoma, or bile duct cancer.
Based on the encouraging activity and safety profile of the dabrafenib-trametinib regimen to date, some oncologists believe cholangiocarcinoma patients should be evaluated for these mutations and given the chance to receive the combination.